L&C BIO (290650) Q1 2026 earnings summary

Executive summary

• Specializes in human tissue grafts, tissue-based medical devices, and cosmeceuticals, with expanding indications and global market entry.

• Major revenue from acellular dermal matrix (ADM) products, especially MegaDerm, with diversified product pipeline and robust R&D.

• Recent expansion includes full acquisition of L&C Bioscience Technology (Kunshan) Co., Ltd, strengthening China operations.

Financial highlights

• Q1 2026 consolidated revenue: KRW 30.3 billion, up from KRW 17.7 billion in Q1 2025.

• Q1 2026 consolidated operating income: KRW 6.0 billion, up from KRW 4.4 billion in Q1 2025.

• Q1 2026 consolidated net income: KRW 2.7 billion, compared to a net loss of KRW 0.6 billion in Q1 2025.

• Basic EPS for Q1 2026: KRW 105, compared to KRW -13 in Q1 2025.

• Cash and cash equivalents at Q1 2026 end: KRW 43.8 billion.

Outlook and guidance

• Focus on expanding indications for tissue grafts and medical devices, targeting both domestic and international markets.

• Continued investment in R&D and product pipeline, with new launches and regulatory approvals expected.

• Ongoing efforts to strengthen global presence, especially in China and Southeast Asia.